BMO Capital Upgrades Beam Therapeutics Inc (BEAM) to Outperform as Risk/Reward 'Skewed to Upside'
Tweet Send to a Friend
(Updated - December 20, 2022 6:38 AM EST)
BMO Capital analyst Kostas Biliouris upgraded Beam Therapeutics Inc (NASDAQ: BEAM) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
BMO Capital analyst Kostas Biliouris upgraded Beam Therapeutics Inc (NASDAQ: BEAM) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
